Brief Report - (2025) Volume 12, Issue 2
Received: 01-Apr-2025, Manuscript No. jpd-26-183902;
Editor assigned: 03-Apr-2025, Pre QC No. P-183902;
Reviewed: 17-Apr-2025, QC No. Q-183902;
Revised: 22-Apr-2025, Manuscript No. R-183902;
Published:
29-Apr-2025
, DOI: 10.37421/2684-4281.2025.12.511
Citation: Ortega, Lucas M.. ”Atopic Dermatitis: Management, Microbiome, and Comorbidities.” J Dermatol Dis 12 (2025):511.
Copyright: © 2025 Ortega M. Lucas This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense pruritus, eczematous lesions, and a compromised skin barrier, often affecting the face and extensor surfaces in infants, and flexural areas in children and adults. Diagnostic criteria such as the Hanifin and Rajka criteria are crucial for its identification [1].
Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has demonstrated significant efficacy and safety in treating moderate-to-severe atopic dermatitis in both pediatric and adult populations. Its mechanism of action involves blocking the signaling of IL-4 and IL-13, key cytokines involved in type 2 inflammation characteristic of AD [2].
The epidermal barrier dysfunction is a central tenet in the pathogenesis of atopic dermatitis, making the skin more susceptible to irritants, allergens, and pathogens. Studies highlight the role of filaggrin gene mutations in compromising epidermal barrier integrity, leading to increased transepidermal water loss and heightened IgE sensitization [3].
Topical calcineurin inhibitors (TCIs), such as tacrolimus and pimecrolimus, are non-steroidal agents that effectively manage mild to moderate atopic dermatitis, particularly in sensitive areas. They work by suppressing T-cell activation and the release of inflammatory cytokines [4].
Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, offers a non-steroidal option for treating mild to moderate atopic dermatitis. Its mechanism involves reducing inflammation by inhibiting PDE4, an enzyme involved in the production of inflammatory mediators [5].
The management of severe and refractory atopic dermatitis often requires systemic therapies. Traditional immunosuppressants like cyclosporine and newer targeted biologics have revolutionized treatment by offering more specific immunomodulation with improved safety profiles [6].
Understanding the role of the microbiome in atopic dermatitis is an evolving area of research. Dysbiosis of the skin microbiome, particularly an imbalance between commensal and pathogenic bacteria, is frequently observed in AD patients. This imbalance contributes to impaired skin barrier function and increased inflammation [7].
Phototherapy, particularly narrowband ultraviolet B (NB-UVB) and psoralen plus ultraviolet A (PUVA), remains a valuable treatment modality for moderate to severe atopic dermatitis refractory to topical therapies. It works by modulating immune responses in the skin and reducing inflammation [8].
Tralokinumab, a human monoclonal antibody that specifically binds to and neutralizes interleukin-13 (IL-13), represents a novel targeted therapy for moderate-to-severe atopic dermatitis. By inhibiting IL-13 signaling, it addresses a key driver of type 2 inflammation [9].
The 'atopic march' describes the common progression of allergic diseases, starting with atopic dermatitis in infancy and often followed by allergic rhinitis and asthma. Early and effective management of AD is thought to potentially mitigate the development or severity of subsequent allergic conditions [10].
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense pruritus, eczematous lesions, and a compromised skin barrier. Key clinical features include characteristic lesion distribution that varies with age, often affecting the face and extensor surfaces in infants, and flexural areas in children and adults. Diagnostic criteria, such as the Hanifin and Rajka criteria, are crucial [1].
Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has demonstrated significant efficacy and safety in treating moderate-to-severe atopic dermatitis in both pediatric and adult populations. Clinical trials show marked improvements in skin clearance, pruritus reduction, and overall quality of life for patients treated with dupilumab compared to placebo [2].
The skin barrier dysfunction is a central tenet in the pathogenesis of atopic dermatitis, making the skin more susceptible to irritants, allergens, and pathogens. Studies highlight the role of filaggrin gene mutations in compromising epidermal barrier integrity, leading to transepidermal water loss (TEWL) and increased IgE sensitization [3].
Topical calcineurin inhibitors (TCIs), such as tacrolimus and pimecrolimus, are non-steroidal agents that effectively manage mild to moderate atopic dermatitis, particularly in sensitive areas like the face and intertriginous regions where long-term corticosteroid use is undesirable. They work by suppressing T-cell activation and the release of inflammatory cytokines [4].
Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, offers a non-steroidal option for treating mild to moderate atopic dermatitis. Its mechanism involves reducing inflammation by inhibiting PDE4, an enzyme involved in the production of inflammatory mediators [5].
The management of severe and refractory atopic dermatitis often requires systemic therapies. Oral corticosteroids, while potent, are generally reserved for short-term use due to significant side effects. Traditional immunosuppressants like cyclosporine, azathioprine, and mycophenolate mofetil are effective but necessitate close monitoring for adverse events [6].
Understanding the role of the microbiome in atopic dermatitis is an evolving area of research. Dysbiosis of the skin microbiome, particularly a decrease in commensal bacteria like *Staphylococcus epidermidis* and an increase in pathogenic bacteria such as *Staphylococcus aureus*, is frequently observed in AD patients [7].
Phototherapy, particularly narrowband ultraviolet B (NB-UVB) and psoralen plus ultraviolet A (PUVA), remains a valuable treatment modality for moderate to severe atopic dermatitis that is refractory to topical therapies. It works by modulating immune responses in the skin, reducing inflammation, and promoting healing [8].
Tralokinumab, a human monoclonal antibody that specifically binds to and neutralizes interleukin-13 (IL-13), represents a novel targeted therapy for moderate-to-severe atopic dermatitis. By inhibiting IL-13 signaling, tralokinumab addresses a key driver of type 2 inflammation [9].
The 'atopic march' describes the common progression of allergic diseases, starting with atopic dermatitis in infancy and often followed by the development of allergic rhinitis and asthma later in childhood. Early and effective management of atopic dermatitis is thought to potentially mitigate the development or severity of subsequent allergic conditions [10].
Atopic dermatitis (AD) is a chronic inflammatory skin condition with key features including pruritus, eczematous lesions, and impaired skin barrier function. Management strategies are tiered, starting with basic skincare and emollients, followed by topical corticosteroids and calcineurin inhibitors for mild to moderate cases. For moderate to severe AD, systemic therapies are employed, including traditional immunosuppressants and newer targeted biologics like dupilumab and tralokinumab. Phototherapy is also an option for recalcitrant cases. Understanding the role of the skin microbiome and managing comorbidities like allergic rhinitis and asthma, as part of the 'atopic march,' are integral to comprehensive care.
None
None
Journal of Dermatology and Dermatologic Diseases received 4 citations as per Google Scholar report
